scholarly journals Hashimoto thyroiditis in mother and thyroid function in offspring – a prospective study

2015 ◽  
Vol 14 (3) ◽  
pp. 9-14
Author(s):  
Agnieszka Zubkiewicz-Kucharska ◽  
◽  
Joanna Chrzanowska ◽  
Anna Noczyńska ◽  
◽  
...  
1987 ◽  
Vol 12 (6) ◽  
pp. 417-420 ◽  
Author(s):  
HENNING LINDEBERG ◽  
JENS U. FELDING ◽  
HELMER SØGAARD ◽  
PETER ILLUM

2018 ◽  
Vol 27 (1) ◽  
pp. 1-7
Author(s):  
Canan Demir ◽  
Cuneyd Anil ◽  
Yusuf Bozkus ◽  
Umut Mousa ◽  
Altug Kut ◽  
...  

Objective: The objective of this study was to assess the antiproliferative pleiotropic effects of statins on thyroid function, volume, and nodularity. Subjects and Methods: One hundred and six hyperlipidemic patients were included in this prospective study. The 69 patients in the statin groups received atorvastatin (16 received 10 mg and 18 received 20 mg) or rosuvastatin (20 received 10 mg and 15 received 20 mg). The 37 patients in the control group, assessed as not requiring drugs, made only lifestyle changes. Upon admission and after 6 months, all patients were evaluated by ultrasonography as well as for lipid variables (total cholesterol, high- and low-density lipoprotein cholesterol, and triglycerides) and thyroid function and structure. Results: After 6 months, no differences in thyroid function, thyroid volume, the number of thyroid nodules, or nodule size were observed in the statin and control groups. In a subgroup analysis, total thyroid volume had decreased more in patients receiving 20 mg of rosuvastatin than that in the control group (p < 0.05). Maximum nodule size had decreased more in those receiving 10 mg of rosuvastatin (p < 0.05). Conclusions: Our results suggest an association between rosuvastatin treatment and smaller thyroid volume and maximum nodule diameter; this could be attributable to the antiproliferative effects of statin therapy on the thyroid.


2012 ◽  
Vol 97 (3) ◽  
pp. 862-870 ◽  
Author(s):  
Avantika C. Waring ◽  
Stephanie Harrison ◽  
Mary H. Samuels ◽  
Kristine E. Ensrud ◽  
Erin S. LeBlanc ◽  
...  

Thyroid ◽  
1996 ◽  
Vol 6 (2) ◽  
pp. 107-110 ◽  
Author(s):  
JENNIFER J. CONN ◽  
MARTIN J. SEBASTIAN ◽  
DAVID DEAM ◽  
MEI TAM ◽  
F.I.R. MARTIN

2013 ◽  
Vol 28 (3) ◽  
pp. 472-479 ◽  
Author(s):  
Avantika C Waring ◽  
Stephanie Harrison ◽  
Howard A Fink ◽  
Mary H Samuels ◽  
Peggy M Cawthon ◽  
...  

2021 ◽  
Author(s):  
Anabela Zunino ◽  
Claudia Vazquez ◽  
Laura Delfino ◽  
Adriana Reyes ◽  
Alicia Lowenstein

Abstract Purpose We performed a prospective study in patients with positive thyroid peroxidase antibodies (TPOAb), to describe their ultrasound (US) patterns and the prevalence of thyroid nodules. Methods In 195 consecutive patients, with positive TPOAb, thyroid US was performed by the same physician and equipment and categorized into four echographic patterns (EP). We determined the prevalence of thyroid nodules and their etiology confirmed by cytology or histology. Results The median TPOAb was 526 IUI/ml. EP1 or normal US was present in 9,7%; EP2 or early/indeterminate stage in 29,4%; EP3 or established thyroiditis in 45,4% and EP4 or advanced/late stage in 15,5% of the patients. TPOAb (median = 857 UI / ml) (p = 0.001), TSH and thyroid volume ​​were higher in EP3. A higher degree of fibrosis was associated with TPOAb > 1000 IU/ml(p = 0,003). Thyroid nodules were reported on US at 47,2% of HT. Fine needle aspiration(FNA) was performed in 49/60 nodules. Cytology: BII: 41 patients (83,7%), B V: 1 patient (2%): suspicious for lymphoma; B VI: 3 patients(6,1%) : Papillary thyroid carcinoma. Benign cytology was present in 56% of EP3 (p = 0,048). Conclusions Higher TPOAb, TSH levels, and thyroid volume were associated with EP3. Fibrosis correlated with TPOAb > 1000 IU/ml. In our population, benign nodules were associated with established thyroiditis patterns. The increased inflammation and immunological activity of Hashimoto thyroiditis (HT) could be a favorable environment for growth factors for benign nodular development.


2021 ◽  
Author(s):  
Alessandro Pizzocaro ◽  
Paolo Colombo ◽  
Walter Vena ◽  
Salvatore Ariano ◽  
Paola Magnoni ◽  
...  

Abstract PurposeTo evaluate the post- coronavirus disease-19 (COVID-19) outcome of thyroid function in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related thyrotoxicosis. MethodsThis was a single-center prospective study involving 29 patients (11 females, 18 males; median age 64 years, range: 43-85) with thyrotoxicosis diagnosed after hospitalization for COVID-19 and then followed-up for a median period of 90 days (range: 30-120) after hospital discharge. At the follow-up, patients were evaluated for serum thyrotropic (TSH), free-thyroxine (FT4), free-triiodiothyronine (FT3), TSH receptor antibodies (TRAb), thyroglobulin antibodies (TgAb), thyroperoxidase antibodies (TPOAb) and ultrasonographic thyroid structure.ResultsAfter recovery of COVID-19, serum TSH values significantly increased (P<0.001) and FT4 values significantly decreased (P=0.001), without significant change in serum FT3 (P=0.572). At the follow-up, 28 subjects (96.6%) became euthyroid whereas overt hypothyroidism developed in one case. At the ultrasound evaluation of thyroid gland, hypoecogenicity was found in 10 patients (34.5%) with a prevalence that was significantly higher in cases with serum TSH > 3.0 mU/l as compared to those with TSH values below 1.0 mU/L (P=0.039). All subjects resulted to be negative for TgAb, TPOAb and TRAb. ConclusionIn a short-term follow-up, thyroid function spontaneously normalized in most subjects with SARS-CoV-2-related thyrotoxicosis. However, thyroid hypoecogenicity was found in a remarkable number of them and future longer-term studies are needed to clarify whether this ultrasonographic alteration may predispose to develop late-onset thyroid dysfunction.


2014 ◽  
Author(s):  
Gesthimani Mintziori ◽  
Efstratios M Kolibianakis ◽  
Grigorios F Grimbizis ◽  
Basil C Tarlatzis ◽  
Dimitrios G Goulis

Sign in / Sign up

Export Citation Format

Share Document